Louis Garguilo's Articles

  1. Hybrid. Continuous. Peptide. Manufacturing. Lilly's Put It All Together. 8/28/2025

    After reading part one with Lilly Kinsdale's Lorraine O'Shea, readers want to learn more about that facility’s “hybrid continuous manufacturing for peptides” technology. Chief Editor Louis Garguilo explores that technology with O'Shea, and ties it into thoughts of CDMO facilities as well.

  2. Lilly's Kinsale Facility Provides A Benchmark For Your CDMO Selection 8/25/2025

    Consider these two questions: How do we select a CDMO? How do we select a facility? The second of these should carry as much weight as the first, but unfortunately often does not. Chief Editor Louis Garguilo thinks that should change. He turns to Eli Lilly's ISPE Award Winning facility, and Lorraine O'Shea, Associate Vice President and Plant Manager at Lilly Kinsale, to make the case.

  3. Biopharma Manufacturing Outsourcing Is Flexible, Not Fractured 8/21/2025

    An element of the 2025 BioPlan Associates annual report and survey took Chief Editor Louis Garguilo by surprise. The report intimates that biopharmaceutical manufacturing faces a fractured CDMO market. Despite solid data to back that assertion up, Garguilo presents a very different view, one based on what many readers have expressed.

  4. As Billions Of Dollars Pour In, Do CDMO Valuations Matter? 8/18/2025

    Customers of a CDMO receiving some of the billions of dollars being invested in CDMOs might be enthusiastic. But large investment into the ownership pool can bring the ripple effects of transition. For some CDMO customers, this positively translates to increased offerings. For others, it introduces complexity and a shift in relationship dynamics. 

  5. Our Supplier Failed? Heck No, We Failed Our Supplier! 8/12/2025

    “We would be in meetings, and someone would disparage a certain CDMO. But one of our leaders would almost always have the opinion that we could make the relationship work. ‘No one is perfect, including us,’ he said.” Outsourcing is an attitude, explains Dan Marasco. Here's the attitude he says you should bring to your external partnerships.

  6. Tech Transfer 2025 – A High-Stakes Game Of Trust 8/4/2025

    Trust us. You'll want to read this editorial from Chief Editor Louis Garguilo, who was (gently) reminded he hadn't visited the subject of tech transfer in a while. He answers the questions both sponsors and CDMOs ask to gain the trust to make a tech transfer work for both sides.

  7. Relationship Equity With CDMOs Is Real, Take It From A Packaging Pro 7/31/2025

    A professional of packaging who has weaved through various positions in Big Pharma says you should understand any points of leverage you have with a CDMO. When leverage is minimal, creating "relationship equity" is key. After a decade interlude, a well-timed follow up conversation with Dan Marasco.

  8. CDMOs Should Stop Stringing Biotechs Along 7/28/2025

    Biotechs, first working closely with a CDMO’s sales manager, experience subsequent and sudden rejections of their projects. Did some of you just wince? If so, that might be because we are again hearing of a problem with sudden rejections after protracted discussions and even site visits. Part two on what is one of the biggest problems for outsourcing today.

  9. The Biggest Problem At CDMOs Today 7/21/2025

    A perennial outsourcing problem has resurfaced, according to industry sources. It is the misalignment at CDMOs between their business development and tech ops or other project-evaluation teams. Sponsors are again encountering situations where CDMO sales/BD show enthusiasm, but later hear the project has been declined. 

  10. The Mighty CDMOs Producing API 7/14/2025

    CDMO focused on active pharmaceutical ingredients (APIs) have long been vital components in the supply chain. Today, they are more than your enablers. CDMO have become strategic actors helping to reshape global outsourcing markets. A new report focuses on the new forces raising their importance.